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High-density lipoprotein cholesterol subfractions
HDL2 and HDL3 are reduced in women with
rheumatoid arthritis and may augment the
cardiovascular risk of women with RA:
a cross-sectional study
Elke Arts1*, Jaap Fransen1, Heidi Lemmers2, Anton Stalenhoef2, Leo Joosten2, Piet van Riel1 and Calin D Popa1
Abstract
Introduction: Higher levels of high density lipoprotein (HDL) subfractions HDL3-chol and particularly HDL2-chol
protect against cardiovascular disease (CVD), but inflammation reduces the HDL level and may impair its anti-
atherogenic effect. Changed HDL composition through the impact of inflammation on HDL subfractions may
contribute to the excess risk of CVD in rheumatoid arthritis (RA). In this study, we investigated whether HDL2-chol
and HDL3-chol concentrations differ between RA patients and healthy controls, and whether these levels are
related to the level of RA disease activity.
Methods: Non-fasting blood samples were collected from 45 RA patients and 45 healthy controls. None of the
participants had a history of CVD, diabetes, or used lipid-lowering drugs. HDL2-chol and HDL3-chol concentrations
were obtained by ultracentrifugation. Regression modeling was used to compare HDL subfraction levels between
RA patients and healthy controls, and to analyze the effect of disease activity on HDL2-chol and HDL3-chol.
Results: HDL2-chol and HDL3-chol were significantly lower in RA patients compared to healthy controls (P = 0.01,
P = 0.005, respectively). The HDL2:HDL3 ratio was significantly lower in patients compared to controls (P = 0.04).
Reduced HDL2-chol and HDL3-chol levels were primarily present in female RA patients and not in male RA patients.
A modest effect of the disease activity score in 28 joins ( DAS28) on HDL2-chol concentrations was found, after
correction for disease duration, glucocorticosteroid use and body mass index (BMI), with a 0.06 mmol/L decrease
with every point increase in DAS28 (P = 0.05). DAS28 did not significantly affect HDL3-chol concentrations (P = 0.186).
Conclusions: Both HDL subfractions but particularly HDL2-chol concentrations were decreased in RA, primarily in
women. This seems to be associated with disease activity and is of clinical relevance. The reduction of the HDL
subfraction concentrations, particularly the supposedly beneficial HDL2-chol, may negatively impact the
cardiovascular risk profile of women with RA.
Introduction
Cardiovascular morbidity and mortality are increased in
the rheumatoid arthritis (RA) population [1-3]. As much
as 50% of all deaths in RA patients can be attributed to
cardiovascular events [1]. The risk of cardiovascular
disease (CVD) in RA is approximately two- to three-fold
greater than in the general population, reaching that of
patients with type 2 diabetes mellitus, according to recent
studies [4]. As traditional risk factors do not fully account
for the increased CVD risk in RA, it can be suggested
that inflammation plays an important role in mediating
cardiovascular risk in these patients [5,6]. In RA it has
been shown that inflammation affects the lipid profile
and accelerates atherosclerosis [7,8]. However, it appears
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that there is no difference in risk of CVD between
patients with low or high disease activity [9]. Apparently,
low levels of inflammation are sufficient to increase CVD
risk in RA.
In the general population, increased levels of total
cholesterol (TC), low-density-lipoprotein cholesterol
(LDL) and triglycerides, and decreased levels of high-
density lipoprotein cholesterol (HDL), that is, a pro-
atherogenic lipid profile, are important risk factors for
CVD [10]. In the general population, HDL is regarded
as the main anti-atherogenic lipoprotein and increased
levels of HDL have been associated with a protective
effect against cardiovascular mortality and morbidity
[11,12]. The beneficial effect of HDL appears to be the
strongest for women [12]. This advantageous effect of
HDL is supposed to be accomplished primarily through
the reverse cholesterol transport (RCT) and the neutrali-
zation of oxidized lipids [13].
In RA patients, however, the effect of changes in lipid
concentrations on CVD risk in RA patients is less
straight forward [8]. Lipoprotein and apolipoprotein
levels are known to fluctuate during the course of RA,
possibly under the influence of inflammation and anti-
inflammatory treatment, including oral steroids and bio-
logic therapies [14-17]. During active disease, increased
levels of TC, triglycerides (TG) and apolipoprotein B
(ApoB), and reduced concentrations of HDL have been
reported [14]. Other aspects of the lipid profile may be
of importance. The inflammatory response in RA
patients may compromise the beneficial anti-atherogenic
effect of HDL on CVD risk. In addition to lower levels
of HDL [14,18,19], inflammation may reduce the anti-
oxidative capacity, impair RCT capacity of HDL in RA
patients, and even lead to HDL becoming pro-inflamma-
tory [20-23]. The functionality of HDL is partially
dependent on HDL composition. Based on its density
HDL can be divided into two main subfractions: HDL2-
cholesterol (HDL2-chol) and the smaller HDL3-choles-
terol (HDL3-chol). HDL2-chol has been suggested to be
the more variable component of total HDL, while it is
higher levels of the HDL2-chol subfraction that contri-
bute to the anti-atherogenic effect of HDL [24-26]. For
that reason, decreased levels of HDL subfractions, parti-
cularly HDL2-chol, could contribute to the risk of CVD
in RA. However, it is currently unclear whether HDL2-
chol and HDL3-chol concentrations are actually
decreased in RA, and whether their levels are associated
with the level of disease activity. Therefore, the objective
of this study was to investigate whether HDL2-chol and
HDL3-chol concentrations differ between RA patients
and healthy controls, and to investigate whether HDL2-
chol and HDL3-chol concentrations are associated with
the level of RA disease activity.
Materials and methods
Study design
This is a cross-sectional study comparing a group of 45
consecutive patients with RA, with a control group of
45 consecutive healthy individuals.
Patients
RA patients were included in the study if they fulfilled
the 1987 American College of Rheumatology classifica-
tion criteria for RA, did not use lipid-lowering drugs, had
no cardiovascular comorbidity (hypertension was
allowed) or diabetes. Disease activity scores (DAS28)
were registered. The controls were consecutively
recruited from healthy blood-donors who came to the
regional blood bank for a donation and were matched for
gender. The donors did not suffer from any inflammatory
or auto-immune disorders and did not use lipid-lowering
drugs, and were free of cardiovascular comorbidity and
diabetes. All patients and controls who were entered in
the study provided their informed consent. The Medical
Ethical Committee Arnhem-Nijmegen approved the
study.
An a priori sample size calculation was deemed inap-
propriate, as evidence regarding HDL2-chol and HDL3-
chol concentrations is limited and no studies have been
performed investigating these concentrations in RA
patients.
Lipoprotein measurements
In both patients and controls, non-fasting blood samples
(30 ml) were collected, using vacutainer tubes (Beckton
Dickinson, Rutherford, New Jersey, USA) containing K3-
ethylenediaminetetraacetic acid (EDTA) (1 mg/ml), and a
sample was taken in a tube without anticoagulant to
obtain serum. Tubes were centrifuged at 3,600 rpm for
10 minutes at 23°C, and frozen at -80°C until assay.
Levels of plasma TC, TG and HDL-cholesterol were
determined enzymatically on an Eroset Hitachi 747 ana-
lyzer which was validated for these particular measure-
ments. During each run, samples from both patients and
controls were analyzed to prevent any within and
between run variability to affect group differences in
HDL subfraction levels. Low-density lipoprotein (LDL)
cholesterol levels were calculated according to the Frie-
dewald formula, which provides reliable values up to a
triglyceride concentration of 4.0 mmol/L. ApoB and A-I
(ApoA) levels (mg/L) were determined by immunone-
phelometry. HDL subfractions were isolated by means of
ultracentrifugation [27]. In short, 2 ml plasma was intro-
duced in MSE (Measuring and Scientific Equipment)
tubes of the ultracentrifuge (Beckman L7-55). KBr and
CBBR (Coomassie Brilliant Blue R) (1.5% solution) was
added and the tubes were centrifuged at 44,000 rpm for
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22 hours at 15°C. HDL2-chol (density 1.08 g/ml) and
HDL3-chol (density 1.149 g/ml) were separated and their
concentrations were measured as previously described
for total HDL, correcting for density and volume (2 ml).
Statistical analyses
The primary outcome was the difference in the concen-
tration of HDL2-chol (mmol/L) between RA patients
and the control group. Secondary outcomes were
between-group differences in HDL3-chol (mmol/L),
HDL2:HDL3 ratio, TC, TG, HDL, LDL-c (mmol/L),
ApoA-I and ApoB (mg/L) levels. The differences in
HDL2-chol and HDL3-chol concentrations and lipopro-
tein levels (TC, TG, LDL-c, HDL, ApoA-I and ApoB)
between RA patients and healthy controls were analyzed
using independent-sample t-tests, with a = 0.05. To
analyze the influence of age and gender on HDL2-chol
and HDL3-chol concentrations, analysis of covariance
was used with HDL2-chol or HDL3-chol concentrations
(mmol/L) as the dependent variable, RA (patient or con-
trol) as independent variable, and gender and age as
covariates and by including an interaction term for gen-
der and presence of RA. To analyze the effect of disease
activity on the HDL2-chol and HDL3-chol concentra-
tions, regression analysis was used with HDL2-chol or
HDL3-chol concentrations as the dependent variable,
disease activity as the independent variable, and regard-
ing age, gender, smoking, BMI, rheumatoid factor posi-
tivity and disease duration as potential confounders.
Additional analyses were performed to investigate the
effect of the inflammatory markers erythrocyte sedimen-
tation rate (ESR; mm/hour) and C-reactive protein
(CRP; mg/L) included in the DAS28. Measured values of
CRP levels <5 mg/L were set at 0 mg/L. Potential con-
founders were added stepwise to the model, with a
change in the regression coefficient of disease activity of
at least 10% as the selection criterion. Mean HDL2-chol
and HDL3-chol levels were determined for patients trea-
ted with glucocorticosteroids, methotrexate and bio-
logicals separately and compared by means of non-
parametric statistics.
Results
Patients and controls
A total of 13 men and 32 women with RA were included
with a mean ± standard deviation (SD) age of 58 ±
10 years and 60 ± 11 years, respectively. The same num-
ber of healthy controls (n = 45) were included, 13 men
and 32 women with a mean ± SD age of 54 ± 6 years and
55 ± 8 years, respectively. The participants in the control
group were on average 5 years younger than the patients
in the RA group (Table 1). Patient characteristics are pre-
sented in Table 1.
Lipid and lipoprotein patterns in RA and controls
HDL subfractions HDL2- and HDL3-chol, and other
lipid and lipoprotein levels, were compared between the
RA and healthy control group. Results are presented in
Table 2. The recovery of HDL after separation into sub-
fractions averaged 95%. The results show that TC and
LDL levels did not differ significantly, while TG and
Apo B levels were significantly higher in RA, and HDL
and Apo A-1 levels were lower (Table 2). Notably, both
HDL sub fractions HDL2-chol (P = 0.01) and HDL3-
chol (P = 0.005) were significantly reduced in RA
patients (Figure 1). Results regarding HDL2-chol con-
centrations demonstrated a larger difference between
RA patients and controls, compared to HDL3-chol, and
consequently the HDL2:HDL3 ratio also was signifi-
cantly lower in RA patients (Table 2).
Influence of age and gender on HDL2-chol and HDL3-chol
concentrations
There appeared to be no association between age and
each of the HDL subfractions HDL2-chol and HDL3-
chol (not shown). In healthy controls, both HDL2-chol
(P < 0.001) and HDL3-chol (P < 0.001) levels were sig-
nificantly higher in women. In RA patients these levels
were not different between men and women (P = 0.13
and P = 0.20, respectively). Therefore, the difference
between RA and healthy controls was analyzed for men
and women separately. In men, the differences between
RA and healthy controls in HDL2-chol (0.011 mmol/L,
95% confidence interval (CI) -0.17 to0.15) and HDL3-
chol (0.007 mmol/L, 95%CI -0.16 to 0.18) were not sig-
nificant (P = 0.89 and P = 0.93, respectively) (Figure 2).
For women, these differences between RA patients and
controls in HDL2-chol (0.27 mmol/L, 95%CI 0.10 to
0.45) and HDL3-chol (0.16 mmol/L, 95%CI 0.08 to 0.23)
were significant (P = 0.003 and P < 0.001, respectively).
After repeating the analyses using linear regression with
an interaction term for group and gender (see methods),
it appeared that there were interactions regarding gen-
der and presence of RA for HDL2-chol (P = 0.055), as
well as for HDL3-chol (P = 0.063). In women, the
HDL2:HDL3 ratio was significantly different between
RA and controls, with a mean difference of 0.2 (95% CI
0.04 to 0.40, P= 0.02) compared to a mean difference of
0.01 (95% CI -0.2 to 0.1, P = 0.9) in men. These findings
are mirrored in TG, ApoA-I and Apo B concentrations.
TG and Apo B levels were significantly increased only
in female RA patients compared to female controls (P =
0.002 and P = 0.005, respectively). Apo A-1 levels were
found to be significantly lower in female RA patients
with a mean difference of 229.8 mg/L (P < 0.001) and
similar in men with a mean difference of 88.6 mg/L
(P = 0.379).
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HDL2-chol, HDL3-chol and disease activity in RA
Figure 3 shows that in RA patients the HDL2-chol and
HDL3-chol concentrations were similar across all cate-
gories of the DAS28 (low <3.2; n = 31, medium 3.2 to 5.1;
n = 6, and high >5.1; n = 8). The effect of disease activity,
as a continuous measure, on HDL2-chol concentrations
was estimated using regression analysis, with gender, age,
disease duration and use of glucocorticosteroids as covari-
ates, while smoking, BMI and rheumatoid factor were not
acting as confounders. A statistically small effect of DAS28
on HDL2-chol was found (Figure 3). HDL2-chol concen-
tration decreased by 0.06 mmol/L with every point increase
in DAS28 (P = 0.05), while correcting for gender, age, dis-
ease duration and use of glucocorticosteroids. Disease
activity did not significantly relate to HDL3-chol, which
decreased by 0.02 mmol/L with every point increase in
DAS28 (P = 0.19), while correcting for gender, age, disease
duration and use of glucocorticosteroids. The inflammatory
marker ESR was significantly associated with HDL2-chol
(P = 0.046) and HDL3-chol (P = 0.006), while correcting
for gender, age, disease duration and use of glucocorticos-
teroids. (CRP did not have a significant effect on either
HDL2-chol or HDL3-chol levels (P = 0.51 and P = 0.21,
respectively). The effect on HDL2- and HDL3-chol for
every point increase in ESR (mm/hour) and CRP (mg/L)
was small; a decrease of 0.006 mmol/L and 0.002 mmol/L,
respectively, in HDL2-chol, and a decrease of 0.004 mmol/L
and 0.002 mmol/L, respectively, in HDL3-chol.
HDL2-chol, HDL3-chol in relation to treatment and
disease duration in RA
Use of (oral) glucocorticosteroids was included as a con-
founder in the analysis of the effect of disease activity on
Table 1 Characteristics of the study participants at baseline.
RA patients (n = 45) Healthy controls (n = 45)
Age, mean ± SD (years) 60 ± 10.1 55 ± 7.8
Female, n (%) 32 (71) 32 (71)
Rheumatoid factor positive, n (%) 40 (89) N/A
DAS28, mean ± SD 3.1 ± 1.7 N/A
ESR, median (P25 to P75) 14 (5 to 28.5) N/A
CRP, median (P25 to P75) 0 (0 to 12) N/A
Smoking, n (%) 16 (32) –
BMI, mean ± SD 25 ± (3.3) –
Anti-rheumatic medication, n (%) 15 (33) N/A
Methotrexate 22 (49) N/A
Other DMARD 11 (24) N.A
Biological DMARD 15 (33) N/A
Oral glucocorticoids, n (%) 8 (18) N/A
BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score (28 joints); DMARD, disease modifying anti-rheumatic drugs; ESR, erythrocyte
sedimentation rate; n, number.
Table 2 Results from the independent-sample t-test of
lipid and lipoprotein levels in RA patients and healthy
controls.
RA patients
(n = 45)
Healthy controls
(n = 45)
P-value
Lipids (mmol/L)
TC, mean ± S D
5.7 ± 1.1 5.7 ± 0.8 0.72
TG, mean ± SD 2.1 ± 1.2 1.6 ± 0.8 0.04
HDL, mean ± SD 1.3 ± 0.3 1.6 ± 0.3 <0.001
HDL2-chol 0.5 ± 0.3 0.7 ± 0.4 0.01
HDL3-chol 0.8 ± 0.2 0.9 ± 0.2 0.005
HDL2:HDL3 0.5 ± 0.3 0.7 ± 0.4 0.04
LDL-c, mean ± SD 3.5 ± 0.9 3.3 ± 0.7 0.41
Lipoproteins (mg/L)
ApoA-I, mean ± SD 1517.2 ± 242.2 1710.1 ± 217.2 <0.001
ApoB, mean ± SD 987.5 ± 220.3 862.2 ± 188.8 0.005
Apo, apolipoprotein; HDL, high density lipoprotein; LDL, low density
lipoprotein; n, number; RA, rheumatoid arthritis; SD, standard deviation; TC,
total cholesterol; TG, triglycerides.
Figure 1 HDL2-chol and HDL3-chol subfractions in RA patients
(RA) and healthy controls (HC). The difference in concentrations
(mmol/L) in HDL2-chol and HDL3-chol between these groups were
compared by means of independent-samples t-test using a = 0.05.
Both HDL sub fractions HDL2-chol (P = 0.01) and HDL3-chol (P =
0.005) were significantly reduced in RA patients. HDL, high density
lipoprotein; RA, rheumatoid arthritis.
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HDL2-chol and HDL3-chol concentrations. The mean ±
SD HDL2-chol and HDL3-chol levels in users and non-
users of methotrexate, biologicals and glucocorticoster-
oids are presented in Table 3. The subanalysis of HDL2-
chol and HDL3-chol levels in non-users and users of
glucocorticosteroids (at the time of the study) showed
moderately lower mean concentrations of HDL2-chol
and moderately higher HDL3-chol levels in users (Table
3), without reaching statistical significance. Glucocorti-
costeroid use and mean prescribed dosage was similar
in men and women (not shown). Disease duration was
considered a confounder as well. In patients with a
longer disease duration (≥10 years) versus patients with
a shorter disease duration (<10 years), higher levels of
both HDL2-chol (mean ± SD 0.6 ± 0.4 versus 0.3 ± 0.1)
and HDL3-chol (mean ± SD 0.9 ± 0.1 versus 0.7 ± 0.2)
concentrations were found. Interestingly, in this study,
women had a longer mean ± SD disease duration (18 ±
11 years versus 8 ± 7 years in men) and a higher mean
± SD DAS28 score (3.4 ± 1.8 versus 2.4 ± 1.2).
Discussion
This study is the first to investigate the distribution of
HDL subfractions in RA patients. According to our
results, both HDL subfractions but particularly HDL2-
chol concentrations were decreased in RA, leading to a
decreased HDL2:HDL3 ratio in these patients. Intrigu-
ingly, the differences in HDL subfractions between RA
and controls were most evident in women, whereas simi-
lar levels of HDL2-chol and HDL3-chol have been
observed in men. Disease activity was not strongly related
to the level of HDL2-chol or HDL3-chol. Finally, our
results suggest that the low HDL2-chol concentration
might contribute to the previously reported increased
cardiovascular risk in RA women.
Results from previous studies investigating HDL and its
anti-atherogenic properties in inflammatory conditions
such as RA, indicate that HDL function deteriorates and
may even become pro-atherogenic in these patients
[20-23]. An inverse relation between HDL3-chol and risk
of CVD has been previously reported [28,29]. When
comparing HDL subfraction levels in cases with CVD
and controls the largest differences were found in HDL2-
chol concentrations, and often stronger inverse associa-
tions between HDL2-chol and CVD were reported
[24-26,30]. This is in accordance with our results; the lar-
gest difference between RA patients and controls was
found in HDL2-chol concentrations, and, consequently,
the HDL2:HDL3 ratio was lower in this group. This fact
might translate into an impaired RCT, one of the crucial
anti-atherogenic mechanisms involving HDL. The RCT
relies on the quantity of both HDL2-chol and HDL3-
chol. Several enzymes, including cholesterylester transfer
protein (CETP) may affect HDL2-chol and HDL3-chol
Figure 2 HDL2-chol and HDL3-chol subfractions in male and female RA patients (RA) and healthy controls (HC). The observed
differences in mean HDL3-chol and particularly HDL2-chol levels (mmol/L) between RA patients and controls were primarily present in women,
not men. In women, the differences between RA patients and healthy controls in HDL2-chol and HDL3-chol were larger; 0.27 mmol/L (95%CI
0.09 to 0.45) for HDL2-chol, and 0.16 mmol/L, (95% CI 0.08 to 0.23) for HDL3-chol. CI, confidence interval; HDL, high density lipoprotein; RA,
rheumatoid arthritis.
Figure 3 HDL2-chol and HDL3-chol concentrations in a group
of RA patients with low, moderate and high disease activity
levels. HDL2-chol and HDL3-chol concentrations were similar across
all categories of the DAS28 (low <3.2; n = 31, medium 3.2 to 5.1; n
= 6, and high >5.1; n = 8). The results of the regression analysis
showed a small effect of DAS28 on HDL2-chol; a decrease in HDL2-
chol of 0.06 mmol/L with every point increase in DAS28 (P = 0.05).
Disease activity did not significantly relate to HDL3-chol, which
decreased by 0.02 mmol/L with every point increase in DAS28 (P =
0.19). DAS28, disease activity score (28 joints); HDL, high density
lipoprotein; n, number; RA, rheumatoid arthritis.
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concentrations, by lowering them [13]. Interestingly,
higher CETP concentrations have been previously indi-
cated in RA patients providing a possible explanation for
the decreased HDL2-chol levels observed in our study
[31]. Lower HDL2-chol levels may impair RCT in these
patients, contributing to accelerated atherosclerosis.
Nevertheless, future research is necessary to clarify the
exact mechanisms responsible for the differences in HDL
subfractions between RA patients and controls.
In our study, HDL2-chol and HDL3-chol concentra-
tions were lower in men compared to women in both
groups investigated. This is in accordance with previous
findings in the general population. Interestingly, the dif-
ferences in subfraction levels that were found between
the RA patients and healthy individuals were only appar-
ent in women, whereas no such differences between male
RA patients and healthy controls were seen. It has been
previously suggested that the excess risk of CVD in RA is
primarily attributable to female RA patients [32,33].
Compared to the general population, the mortality rate
in RA is increased in both men and women, but mortality
from all cardiac causes is larger in women than in men
[34]. Hence, it is tempting to speculate that the excess
CVD risk in RA women might be partly due to the rela-
tive reduction in the beneficial HDL subfraction HDL2-
chol. This is supported by previous findings that show a
decrease in HDL and HDL2-chol concentrations in post-
menopausal women compared to pre-menopausal
women [35], a transition that is reported to induce an
increase in the risk of CVD, although modest, supposedly
due to a decrease in endogenous estrogen [36-38]. Never-
theless, it is unlikely that serum estrogen decisively con-
tributed to the differences in HDL-2 observed in the
present study, as it has been demonstrated to be unal-
tered in RA women [39]. Alternatively, some differences
in RA-related parameters between men and women may
have contributed to this result. In line with that, we
observed that RA women in this study had longer disease
duration and higher mean disease activity. However,
there is inconsistent evidence of a certain influence of
cumulative disease activity on the lipid profile in RA
patients. We have previously shown that disease activity
and disease duration are not strongly associated with car-
diovascular risk, except perhaps longstanding remission
[9,40]. Others, in turn, have indicated that disease dura-
tion is associated with accelerated atherogenesis and evi-
dence of increased carotid intima-media wall thickness
[41] or presence of carotid plaques [42]. Further research
is needed in order to shed more light into this interesting
issue.
Our results show that in the RA group, there is a modest
association between DAS28 and HDL2-chol concentration
and no apparent relationship between DAS28 and HDL3-
chol concentrations. For each 1.0 increment of the
DAS28, HDL-2chol decreased by 0.06 mmol/L. If disease
activity in a patient increases from a very low to a high
DAS28 score by 3.1 points, from 2.0 to 5.1, theoretically
the HDL2-chol concentration would decrease 0.19 mmol/
L. Although on a statistical level these differences did not
prove to be significant, it is likely that such an effect, if
sustained for a longer period of time, would become clini-
cally relevant [43]. Hence, successful suppression of dis-
ease activity by means of treatment may also have a
clinically relevant effect on risk of CVD by augmenting
HDL2-chol and HDL3-chol levels. Due to the limited
number of RA patients who were investigated, we were
unable to find consistent differences between the various
treatment strategies regarding HDL subfraction levels.
This is an interesting issue to pursue in future research.
There are several limitations of this study that require
consideration. Data regarding variables that could be pos-
sible confounders in the analysis of lipid concentrations,
such as smoking and BMI were not available for the
healthy controls and were, therefore, not included in the
analysis. Although it is unlikely that differences in these
variables between RA patients and controls are of suffi-
cient size to yield biased results, patients and controls
were matched on age and gender and randomly selected
to prevent selection bias. Also, this is a cross-sectional
study and, therefore, no long-term effects are reported.
Hence, prolonged exposure to high disease activity or
remission over time and the possible effect on HDL com-
position as well as possible changes in HDL composition
before and during the course of RA require further
research. Further, lipid measurements were performed
using non-fasting blood samples, possibly affecting cho-
lesterol levels. However, HDL concentrations are less
likely to be affected [44,45].
Table 3 Mean HDL2-chol and HDL3-chol levels in RA patients treated with methotrexate, biologicals and
glucocorticosteroids at the time of the study.
Methotrexate Biologicals Glucocorticosteroids
Yes
N = 22
No
N = 23
P Yes No P Yes No P
HDL2-chol (mmol/L) mean ± SD 0.47 ± 0.4 0.46 ± 0.3 0.70 0.42 ± 0.2 0.49 ± 0.4 0.83 0.43 ± 0.2 0.48 ± 0.4 0.87
HDL3-chol (mmol/L) mean ± SD 0.82 ± 0.2 0.83 ± 0.2 0.94 0.82 ± 0.2 0.84 ± 0.2 0.36 0.86 ± 0.1 0.81 ± 0.2 0.34
HDL, high density lipoprotein; N, number; RA, rheumatoid arthritis; SD, standard deviation.
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Conclusions
In conclusion, levels of HDL and both HDL2-chol and
HDL3-chol, but particularly HDL2-chol, were decreased
in female RA patients but not in male patients, compared
to healthy controls. This also affected the HDL2:HDL3
ratio, which decreased in RA. Disease activity level seems
to be related to the level of HDL2-chol and HDL3-chol,
albeit in a modest association. This abnormal HDL-sub-
fraction pattern may negatively impact the risk of CVD
in RA patients, particularly women. Larger prospective
studies would be further necessary in order to test this
hypothesis.
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